Cargando…

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and intermediate‐dose anticoagulation, is superior to prophylactic‐dose anticoagulation in the treatment of COVID‐19. This meta‐analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorda, Anselm, Siller‐Matula, Jolanta M., Zeitlinger, Markus, Jilma, Bernd, Gelbenegger, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015466/ https://www.ncbi.nlm.nih.gov/pubmed/34862791 http://dx.doi.org/10.1002/cpt.2504

Ejemplares similares

Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
por: Jorda, Anselm, et al.
Publicado: (2022)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
por: Jorda, Anselm, et al.
Publicado: (2022)

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
por: Jorda, Anselm, et al.
Publicado: (2020)

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis
por: Grajek, Stefan, et al.
Publicado: (2021)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention
por: Siller-Matula, Jolanta M., et al.
Publicado: (2014)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report
por: Schnaubelt, Sebastian, et al.
Publicado: (2020)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?
por: Jasiewicz, Małgorzata, et al.
Publicado: (2023)

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation
por: Siller-Matula, Jolanta M., et al.
Publicado: (2020)

Pulmonary Aspergillosis in Critically Ill COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study
por: Bergmann, Felix, et al.
Publicado: (2023)

Early Bacterial Coinfections in Patients Admitted to the ICU With COVID-19 or Influenza: A Retrospective Cohort Study
por: Bergmann, Felix, et al.
Publicado: (2023)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study
por: Jorda, Anselm, et al.
Publicado: (2023)

Colistin dampens fibrinolysis and endothelial activation during endotoxaemia: A randomised, double blind trial
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Clopidogrel in Critically Ill Patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
por: Schnabel, Renate B, et al.
Publicado: (2023)

Diclofenac in vitro microdialysis study comparing different experimental set‐ups to improve quantitative recovery
por: Jorda, Anselm, et al.
Publicado: (2022)

Inhaled budesonide for early treatment of COVID-19
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

ANTICOAGULATION AND COVID-19: A META-ANALYSIS
por: Ho, Kam Sing, et al.
Publicado: (2020)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality
por: Donà, Carolina, et al.
Publicado: (2022)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tth8ct3pp6siiu958coi0rtfqr